High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: Need for large scale prevention programs

Anneli Uusküla, Mart Kals, Kristiina Rajaleid, Katri Abel, Ave Talu, Kristi Rüütel, Lucy Platt, Tim Rhodes, Jack DeHovitz, Don Des Jarlais

Research output: Contribution to journalArticle

Abstract

Objective: To examine HIV risk behavior and HIV infection among new injectors in Tallinn, Estonia. Design and methods: Data from two cross-sectional surveys of injecting drug users (IDUs) recruited from a syringe exchange program (N = 162, Study 1) or using respondent driven sampling (N = 350, Study 2). Behavioral surveys were administered; serum samples were collected for HIV testing. Subjects were categorized into new injectors (injecting ≤ 3 years) and long-term injectors (injecting > 3 years). Results: Twenty-eight of 161 (17%, Study 1) and 73/350 (21%, Study 2) of the study subjects were new injectors. HIV infection was substantial among the newer injectors: HIV prevalence was 50% (Study 1) and 34% (Study 2), and estimated HIV incidence 31/100 PY and 21/100 PY, respectively. In Study 2, new injectors were more likely to be female and ethnic Estonian and less likely to be injecting daily compared with long-term injectors. No significant difference was found among two groups on sharing injecting equipment or reported number of sexual partners. Conclusions: A continuing HIV epidemic among new injectors is of critical public health concern. Interventions to prevent initiation into injecting drug use and scaling up HIV prevention programs for IDUs in Estonia are of utmost importance.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalJournal of Public Health
Volume30
Issue number2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Estonia
Drug Users
HIV Infections
HIV
Incidence
Needle-Exchange Programs
HIV-2
Sexual Partners
Risk-Taking
Public Health
Cross-Sectional Studies
Equipment and Supplies
Serum
Pharmaceutical Preparations

Keywords

  • Estonia
  • HIV
  • IDU
  • Injection drug use
  • New injecting drug users

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia : Need for large scale prevention programs. / Uusküla, Anneli; Kals, Mart; Rajaleid, Kristiina; Abel, Katri; Talu, Ave; Rüütel, Kristi; Platt, Lucy; Rhodes, Tim; DeHovitz, Jack; Des Jarlais, Don.

In: Journal of Public Health, Vol. 30, No. 2, 01.06.2008, p. 119-125.

Research output: Contribution to journalArticle

Uusküla, Anneli ; Kals, Mart ; Rajaleid, Kristiina ; Abel, Katri ; Talu, Ave ; Rüütel, Kristi ; Platt, Lucy ; Rhodes, Tim ; DeHovitz, Jack ; Des Jarlais, Don. / High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia : Need for large scale prevention programs. In: Journal of Public Health. 2008 ; Vol. 30, No. 2. pp. 119-125.
@article{94334ede01ed4640a6fc503ebf1826be,
title = "High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: Need for large scale prevention programs",
abstract = "Objective: To examine HIV risk behavior and HIV infection among new injectors in Tallinn, Estonia. Design and methods: Data from two cross-sectional surveys of injecting drug users (IDUs) recruited from a syringe exchange program (N = 162, Study 1) or using respondent driven sampling (N = 350, Study 2). Behavioral surveys were administered; serum samples were collected for HIV testing. Subjects were categorized into new injectors (injecting ≤ 3 years) and long-term injectors (injecting > 3 years). Results: Twenty-eight of 161 (17{\%}, Study 1) and 73/350 (21{\%}, Study 2) of the study subjects were new injectors. HIV infection was substantial among the newer injectors: HIV prevalence was 50{\%} (Study 1) and 34{\%} (Study 2), and estimated HIV incidence 31/100 PY and 21/100 PY, respectively. In Study 2, new injectors were more likely to be female and ethnic Estonian and less likely to be injecting daily compared with long-term injectors. No significant difference was found among two groups on sharing injecting equipment or reported number of sexual partners. Conclusions: A continuing HIV epidemic among new injectors is of critical public health concern. Interventions to prevent initiation into injecting drug use and scaling up HIV prevention programs for IDUs in Estonia are of utmost importance.",
keywords = "Estonia, HIV, IDU, Injection drug use, New injecting drug users",
author = "Anneli Uusk{\"u}la and Mart Kals and Kristiina Rajaleid and Katri Abel and Ave Talu and Kristi R{\"u}{\"u}tel and Lucy Platt and Tim Rhodes and Jack DeHovitz and {Des Jarlais}, Don",
year = "2008",
month = "6",
day = "1",
doi = "10.1093/pubmed/fdn014",
language = "English (US)",
volume = "30",
pages = "119--125",
journal = "Journal of Public Health",
issn = "1741-3842",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia

T2 - Need for large scale prevention programs

AU - Uusküla, Anneli

AU - Kals, Mart

AU - Rajaleid, Kristiina

AU - Abel, Katri

AU - Talu, Ave

AU - Rüütel, Kristi

AU - Platt, Lucy

AU - Rhodes, Tim

AU - DeHovitz, Jack

AU - Des Jarlais, Don

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Objective: To examine HIV risk behavior and HIV infection among new injectors in Tallinn, Estonia. Design and methods: Data from two cross-sectional surveys of injecting drug users (IDUs) recruited from a syringe exchange program (N = 162, Study 1) or using respondent driven sampling (N = 350, Study 2). Behavioral surveys were administered; serum samples were collected for HIV testing. Subjects were categorized into new injectors (injecting ≤ 3 years) and long-term injectors (injecting > 3 years). Results: Twenty-eight of 161 (17%, Study 1) and 73/350 (21%, Study 2) of the study subjects were new injectors. HIV infection was substantial among the newer injectors: HIV prevalence was 50% (Study 1) and 34% (Study 2), and estimated HIV incidence 31/100 PY and 21/100 PY, respectively. In Study 2, new injectors were more likely to be female and ethnic Estonian and less likely to be injecting daily compared with long-term injectors. No significant difference was found among two groups on sharing injecting equipment or reported number of sexual partners. Conclusions: A continuing HIV epidemic among new injectors is of critical public health concern. Interventions to prevent initiation into injecting drug use and scaling up HIV prevention programs for IDUs in Estonia are of utmost importance.

AB - Objective: To examine HIV risk behavior and HIV infection among new injectors in Tallinn, Estonia. Design and methods: Data from two cross-sectional surveys of injecting drug users (IDUs) recruited from a syringe exchange program (N = 162, Study 1) or using respondent driven sampling (N = 350, Study 2). Behavioral surveys were administered; serum samples were collected for HIV testing. Subjects were categorized into new injectors (injecting ≤ 3 years) and long-term injectors (injecting > 3 years). Results: Twenty-eight of 161 (17%, Study 1) and 73/350 (21%, Study 2) of the study subjects were new injectors. HIV infection was substantial among the newer injectors: HIV prevalence was 50% (Study 1) and 34% (Study 2), and estimated HIV incidence 31/100 PY and 21/100 PY, respectively. In Study 2, new injectors were more likely to be female and ethnic Estonian and less likely to be injecting daily compared with long-term injectors. No significant difference was found among two groups on sharing injecting equipment or reported number of sexual partners. Conclusions: A continuing HIV epidemic among new injectors is of critical public health concern. Interventions to prevent initiation into injecting drug use and scaling up HIV prevention programs for IDUs in Estonia are of utmost importance.

KW - Estonia

KW - HIV

KW - IDU

KW - Injection drug use

KW - New injecting drug users

UR - http://www.scopus.com/inward/record.url?scp=44649187857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649187857&partnerID=8YFLogxK

U2 - 10.1093/pubmed/fdn014

DO - 10.1093/pubmed/fdn014

M3 - Article

C2 - 18308743

AN - SCOPUS:44649187857

VL - 30

SP - 119

EP - 125

JO - Journal of Public Health

JF - Journal of Public Health

SN - 1741-3842

IS - 2

ER -